A Case of Miller Fisher Syndrome Due to the Use of Cemiplimab

J Neuroophthalmol. 2021 Sep 1;41(3):e343-e345. doi: 10.1097/WNO.0000000000001062.

Authors

Arko Ghosh¹, Shruthi Harish Bindiganavile, Nita Bhat, Andrew G Lee

Affiliation

¹ Texas A&M University College of Medicine (AG, AGL), Bryan, Texas; Department of Ophthalmology (SHB, NB, AGL), Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas; Departments of Ophthalmology, Neurology, and Neurosurgery (AGL), Weill Cornell Medicine, New York, New York; Department of Ophthalmology (AGL), University of Texas Medical Branch, Galveston, Texas; University of Texas MD Anderson Cancer Center (AGL), Houston, Texas; and Department of Ophthalmology (AGL), The University of Iowa Hospitals and Clinics, Iowa City, Iowa.

PMID: 32868575
DOI: 10.1097/WNO.0000000000001062

No abstract available

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use
Carcinoma, Squamous Cell / drug therapy
Eye Movements / drug effects*
Humans
Hydroxyethylrutoside
Male
Miller Fisher Syndrome / chemically induced*
Miller Fisher Syndrome / complications
Miller Fisher Syndrome / diagnosis
Ophthalmoplegia / etiology*
Ophthalmoplegia / physiopathology
Skin Neoplasms / diagnostic imaging

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Hydroxyethylrutoside
cemiplimab